Acorda Discontinues Dalfampridine for Treatment of Post-Stroke Mobility Issues

Acorda Therapeutics (NASDAQ:ACOR) has announced that results from its MILESTONE clinical study did not support continued development of dalfampridine as a treatment for post-stroke mobility issues.
According to the press release:

“The Company elected to stop enrollment and to conduct an unblinded analysis of the MILESTONE trial after reaching enrollment of 377 participants … The study found that 23 of 121 (19.0%) participants receiving 10 mg of dalfampridine BID and 17 of 121 (14.0%) participants receiving 7.5 mg of dalfampridine BID showed at least a 20% improvement on the 2MinWT, compared to 17 of 126 (13.5%) participants receiving placebo.”

Acorda’s CEO, Ron Cohen, said the following:

“This outcome underscores the risks that companies in the biopharmaceutical industry must take in order to develop innovative medicines. Over the past three years, we have successfully diversified our pipeline portfolio to account for this risk.”

Read the full press release here.